Kunze I, Glahn J, Busse O
Neurologische Klinik, Klinikums Minden.
Nervenarzt. 1991 Aug;62(8):477-82.
Heparin therapy in acute stroke is a controversial issue. It is uncertain, whether heparin has a therapeutic or preventive effect in the early phase of the stroke. From 1984-1989, 1095 patients with acute ischemic stroke were treated, 141 (12.9%) of whom received heparin within 3 days of stroke onset. The mean duration of heparin anticoagulation was 10 days. In 28 cases (20%), heparin was used as antithrombotic agent (25/28 patients suffered a basilar artery occlusion, of whom 22 died). In 113 cases (80%), heparin was used in embolic stroke to prevent recurrence (24% cardioembolic stroke, 54% arterio-arterial embolism, and 22% embolism of unknown etiology). The rate of recurrent stroke in the early phase was 13% with a persistent deficit in 5.3%. The results are comparable with those of other trials reported in the literature. Only 2 patients had an anticoagulation-related haemorrhage with clinical deterioration. Heparin anticoagulation in acute stroke is a low-risk therapy, but its preventive value has not yet been demonstrated.
肝素疗法在急性卒中治疗中是一个存在争议的问题。肝素在卒中早期是否具有治疗或预防作用尚不确定。1984年至1989年期间,对1095例急性缺血性卒中患者进行了治疗,其中141例(12.9%)在卒中发作后3天内接受了肝素治疗。肝素抗凝的平均持续时间为10天。28例(20%)患者将肝素用作抗血栓药物(28例患者中有25例患有基底动脉闭塞,其中22例死亡)。113例(80%)患者在栓塞性卒中中使用肝素以预防复发(心源性栓塞性卒中占24%,动脉-动脉栓塞占54%,病因不明的栓塞占22%)。早期卒中复发率为13%,持续性神经功能缺损率为5.3%。这些结果与文献中报道的其他试验结果相当。仅有2例患者出现与抗凝相关的出血且临床症状恶化。急性卒中时肝素抗凝是一种低风险治疗方法,但其预防价值尚未得到证实。